SRI International Awarded Department of Defense Contract to Develop Drug to Protect Soldiers from Chemical Warfare Agents  
3/20/2007 12:33:47 PM

MENLO PARK, Calif.--(BUSINESS WIRE)--SRI International, an independent nonprofit research and development organization, today announced that it has been awarded a comprehensive contract by the U.S. Department of Defense (DoD) to develop and deliver 90,000 doses of a prophylactic drug that will protect soldiers against poisoning by organophosphorus (OP) nerve agents.